Cigna Specialty Care Options programs drug list expansion

April 1, 2024

Our Cigna Specialty Care OptionsSM (SCO) and Cigna Specialty Care Options PlusSM (SCO+) programs identify customers whose nononcology and oncology specialty medications are being administered in a higher-intensity setting (e.g., outpatient hospital) to determine whether a less-intensive site of care is clinically appropriate. These customers are identified at the time of prior authorization.

The SCO and SCO+ programs contain a medical necessity site-of-care review for select oncology products in accordance with our Medication Administration Site of Care coverage policy.

When clinically appropriate, we redirect customers to a quality, less-intensive site of care, such as a contracted provider’s office, a customer’s home with infusion nurses, or a non-hospital-based ambulatory infusion center. In certain circumstances, procurement from a specialty pharmacy with which we have a reimbursement arrangement may be an option.

SCO and SCO+ drug list expansion

We recently expanded the SCO and SCO+ drug lists to include the specialty medical injectables listed below.

SCO Injectables
Brand nameGeneric nameSite of care addition date
CONSENTYX® intravenous formulation(secukinumab)November 20, 2023
ALYGLOTM(immune globulin intravenous, human-stwk)April 9, 2024
Tyenne®(tocilizumab-aazg)May 17, 2024
TofidenceTM(tocilizumab-bavi)June 24, 2024
Zymfentra®(inflizimab-dyyb)June 24, 2024
Piasky®(crovalimab-akkz)July 31, 2024
Kisunla®(donanemab-azbt)August 22, 2024
SCO+ Injectables
Brand nameGeneric nameSite of care addition date
OmvohTM(mirikizumab-mrkz)December 4, 2023
Tecentriq Hybreza ®(atezolizumab, hyaluronidase-tqjs)October 1, 2024
UDENYCA®(pegfilgrastim-cbqv)February 6, 2024
LOQTORZITM(toripalimab-tpzi)February 6, 2024

SCO and SCO+ drug list

To access the SCO and SCO+ drug list, log in to the Cigna for Health Care Professionals website (CignaforHCP.com) > Resources > Reimbursement and Payment Policies > Precertification Policies > Specialty Care Options and Specialty Care Options Plus Drug List. We recommend you review this list frequently, as it is subject to change. Specialty medical injectables may be added upon U.S. Food & Drug Administration approval.

How are we doing?

Please let us know what you think of the Provider Newsroom information and news.

Contact Us